SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 22nd, 2024 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2024, between INmune Bio Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
WARRANT TO PURCHASE SHARES OF COMMON STOCK INMUNE BIO INC.Warrant to Purchase Shares of Common Stock • April 22nd, 2024 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00pm (New York City time) on the earlier of (1) the two (2) year anniversary of the Initial Exercise Date or (2) thirty (30) Trading Days following the reporting of top line data (EMACC) in the Phase 2 Alzheimer’s program of XPro1595, (the “Termination Date”) but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company’s common stock, such officers, directors or affiliates will have an additional 60 days from the terminat
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • April 22nd, 2024 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
